Biofrontera Inc.Biofrontera Inc.Biofrontera Inc.

Biofrontera Inc.

No trades
See on Supercharts
Market capitalization
‪6.04 M‬USD
−5.9233USD
‪−20.13 M‬USD
‪34.07 M‬USD
‪3.27 M‬
Beta (1Y)
−2.54

About Biofrontera Inc.


CEO
Hermann Lübbert
Headquarters
Woburn
Founded
2015
FIGI
BBG013841CP0
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Displays a symbol's price movements over previous years to identify recurring trends.